



Intercell receives EUR 1 million milestone payment from partner sanofi pasteur for bacterial vaccine candidate

Vienna, Austria, January 9, 2006 – Intercell AG (VSE, “ICLL”) announced today that the next milestone within the collaboration with sanofi pasteur for the development of a bacterial vaccine has successfully been achieved. This significant progress within the preclinical development of a bacterial vaccine candidate resulted in another milestone payment of EUR 1 million for Intercell .

In July 2005, sanofi pasteur exercised its option on exclusive worldwide commercial rights on certain bacterial vaccine antigens, which have been identified by Intercell’s Antigen Identification Program. Over the entire term of the agreement, Intercell will be entitled to further milestone based license payments totaling to about EUR 20 million, as well as royalties on future net sales. The EUR 1 million milestone payment received now will be accounted for as revenue of the financial year 2005.

The vaccine candidate, which has the potential to address an important unmet medical need in the field of infectious diseases, was licensed from Intercell under a collaboration and license option agreement signed in December 2003. The parties have agreed confidentiality on the indication.

“We’re pleased about this significant progress in the development of a bacterial vaccine candidate fully derived from our proprietary Antigen Identification Program within our collaboration with sanofi pasteur,” commented Gerd Zettlmeissl, CEO of Intercell AG. “This emphasizes once again the value and potential of our technologies for the development of novel vaccines.”

About Intercell

Intercell AG is a fast growing biotechnology company focusing on the design and development of novel vaccines for prevention and treatment of diseases with substantial unaddressed medical need. The Company’s unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell’s technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, a partnered Tuberculosis vaccine as well as a partnered *S. aureus* vaccine in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL”. For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2 – A-1030 Vienna

P: +43-1-20620-303 – kwieser@intercell.com





This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.